Breast Cancer

Patricia Jakel, RN, MN, AOCN, ended up on the opposite of the bed than she was used to when she was diagnosed with stage III invasive lobular breast cancer.

The FDA has approved the co-packaging of oral medication ribociclib and letrozole, used to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women.

Nurses at the Stefanie Spielman Comprehensive Breast Center at the James Cancer Hospital at Ohio State University assessed the treatment standards for patients with breast cancer who are pregnant.

Carolyn Phillips, MSN, RN, ACNP-BC, AOCNP, discusses the unique experienes of young adult patients in their 20x with breast cancer.

Joaimee Cutrone, BSN, RN, discusses the importance of awareness for male breast cancer.

Eric Vachon, BSN, PhD candidate, discusses the importance of taking all variables of complexity into account when considering adherence to kinase inhibitors.

Seven professional organizations came together to issue a new position statment on recommendations for treating patients with aromatase-inhibitor-related bone loss (AIBL).

A recent study indicates that the use of bilateral mastectomy to treat women with ductal carcinoma in situ is unnecessary.

A recent study evaluated the effect of red light on hair growth in women with breast cancer.

Second primary cancers that occur in pediatric, adolescent and young adult (AYA) patients are deadlier than those that occur in older patients.

The Paxman Scalp Cooling System has been granted FDA clearance to reduce hait loss in patients with breast cancer recieving chemotherapy.

An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

With more patients diagnosed with breast cancer looking to contralateral prophylactic mastectomy, it is important that surgeons discuss this procedure in-depth so patients can better understand.

Language barriers can mean patients put off preventive screenings, and even treatment, for fear of being misunderstood by their healthcare providers.

Thought the incidence of breast cancer has decreased in many US racial/ethnic populations, the rate has increased in the Asian-American population.

Angie Meillier, RN, MS, CPPM, discusses the importance of shared decision making and patient understanding in breast cancer and throughout oncology.

Fewer people are dying from cancer than years ago, according to a recent study.

Expert Adam M. Brufsky, MD, PhD, discusses the considerations for bone-targeted agents denosumab and zoledronic acid (Zometa) in patients with breast cancer.

For patients with breast cancer on aromatase inhibitors, preventive sexual counseling can reduce sexual dysfunction, and it should be provided earlier in treatment, with support from providers.

A recent study evaluated how muscle mass can be used to predict which patients will experience toxicities from chemotherapy and to what extent.

The PARP inhibitor olaparib improved PFS when compared to standard chemotherapy in patients with BRCA-positive breast cancer, according to findings from the phase III OLYMPIAD trial.

The FDA has granted approval to ribociclib (Kisqali) for firstline treatment of HR+/HER2- breast cancer.

According to findings presented at the 2017 Miami Breast Cancer Conference, combination eribulin and pembrolizumab showed promising results for patients with metastatic triple-negative breast cancer (TNBC).

For patients who may be unable to afford access to scalp cooling systems for chemotherapy-induced hair loss, the nonprofit organization Hair to Stay can help with their grants.